



Intravenous Immunoglobulin and Methylprednisolone Refractory Multisystem Inflammatory Syndrome in Children (MIS-C) in Steroid-Dependent Nephrotic Syndrome Following Rituximab

Priyankar Pal¹ · Saugat Ghosh¹ · Kaustabh Chaudhuri¹ · Rajiv Sinha¹

Received: 9 August 2022 / Accepted: 21 November 2022
© The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation 2022

To the Editor: A 9-y-old male, known steroid-dependent nephrotic syndrome patient, on alternate-day prednisolone, and having received rituximab 10 d back, presented with high fever and maculopapular rashes for 2 d. On admission, he was in shock, which was diagnosed as septic shock. Fluid resuscitation and inotropes were started. 2D echo revealed global dyskinesia of the heart and an ejection fraction (EF) 40%. COVID IgG level was 8719.6 (cutoff < 60 AU/mL), NT-proBNP was 26202 pg/mL (< 300 pg/mL), D-dimer was 6252.7 ng/mL (< 500 ng/mL), ferritin was 1595 ng/mL (< 150 ng/mL), IL-6 was 743.9 pg/mL (< 43 pg/mL), CRP was 26.5 mg/dL, and procalcitonin was 27.4 ng/mL. Cultures were negative.

The diagnosis was revised to MIS-C; IVIg 1 g/kg and methylprednisolone 10 mg/kg were initiated, but fever spikes persisted with hypotension, and the EF lowered to 20%. Methylprednisolone was increased to 1 g/d but on day 3, platelets dropped to 45000/cmm and ferritin elevated to 16585, INR 3.5, SGPT 4540 IU/L, and creatinine 2.1 mg/dL. Considering a refractory hypercytokinemic state with multiorgan dysfunction, he was administered the IL-6 inhibitor tocilizumab IV, 8 mg/kg. Fever and inflammatory markers decreased, and EF improved to 50% over the next 3 d.

Post-COVID MIS-C is a life-threatening condition; IVIg and steroids being the mainstays of treatment, with an overall good prognosis if diagnosed and treated rapidly. The data over the last 2 y showed that patients on rituximab fared poorly following COVID-19 infection [1], but there are no reports on the severity of MIS-C in post-Rituximab patients. Our patient received rituximab, which induces trogocytosis of B-cells, resulting in acute production and release of IL-6 [2]. IL-6 concentrations are elevated in critically ill MIS-C

patients, and hence is implicated in diagnosis, prognosis, and more importantly, the use of tocilizumab in treatment [3, 4].

Our patient had stormy presentation with cardiogenic shock on day 2 of fever, showed rapidly increasing severity in spite of IVIg and steroids, and finally responded to tocilizumab. This is the first reported case of post-rituximab MIS-C.

Declarations

Conflict of Interest None.

References

1. Andersen KM, Bates BA, Rashidi ES et al; National COVID Cohort Collaborative Consortium. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. *Lancet Rheumatol.* 2022;4:e33–e41.
2. Jones JD, Hamilton BJ, Skopelja S, Rigby WF. Induction of interleukin-6 production by rituximab in human B cells. *Arthritis Rheumatol.* 2014; 66:2938–46.
3. Diaz F, Bustos BR, Yagnam F, et al. Comparison of interleukin-6 plasma concentration in multisystem inflammatory syndrome in children associated with SARS-CoV-2 and pediatric sepsis. *Front Pediatr.* 2021;9:756083.
4. Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV. Hyper-inflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. *Indian Pediatr.* 2020;57:681–3.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Priyankar Pal
mailme.priyankar@gmail.com

¹ Department of Pediatrics, Apollo Hospitals, Kolkata, West Bengal, India